Women With Oestrogen Receptor Positive Early Breast Cancer Should Receive Aromatase Inhibitors Upfront - New NICE Clinical Guidelines
AstraZeneca welcomes the National Institute for Health and Clinical Excellence (NICE) Early Breast Cancer (EBC) clinical guideline (1) that recommends upfront use of aromatase inhibitors (AIs), such as anastrozole (Arimidex),Anastrozole (Arimdex)(2) in women who are not deemed to be low risk, which will help to ensure that postmenopausal women with oestrogen (ER) positive EBC receive the most appropriate treatment available. (Source: Cardiovascular / Cardiology News From Medical News Today)div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div
Potential Benefits Of Novel Leukemia Treatment
Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually. Recently published in the journal Blood, the results of a study led by Steven Grant, M.D... (Source: Health News from Medical News Today)
